West Virginia is currently home to 338 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Morgantown, Charleston, Huntington and Wheeling. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )
NCT05568888
Recruiting
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.
Gender:
All
Ages:
15 years and above
Trial Updated:
06/03/2024
Locations: J.W. Ruby Memorial Hospital, Morgantown, West Virginia
Conditions: Traumatic Injury
Register for Updates
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096
Recruiting
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Research Site, Morgantown, West Virginia
Conditions: Generalized Myasthenia Gravis
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
All
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Hoops Family Children's Hospital at Marshall University, Huntington, West Virginia
Conditions: Bronchiolitis Acute Viral
Register for Updates
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996
Recruiting
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination wit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: West Virginia University Hospitals Inc, Morgantown, West Virginia
Conditions: Early Breast Cancer
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
Female
Ages:
Between 18 years and 60 years
Trial Updated:
05/31/2024
Locations: United Hospital Center, Bridgeport, West Virginia
Conditions: Breast Cancer
Register for Updates
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
All
Ages:
Between 50 years and 70 years
Trial Updated:
05/31/2024
Locations: Edwards Comprehensive Cancer Center, Huntington, West Virginia
Conditions: Stage I Breast Cancer
Register for Updates
Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
NCT04419779
Recruiting
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham... Read More
Gender:
All
Ages:
Between 21 years and 70 years
Trial Updated:
05/31/2024
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Type 2 Diabetes
Register for Updates
Rural Adult and Youth Sun Protection Study
NCT06439979
Recruiting
The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.
Gender:
All
Ages:
Between 3 years and 7 years
Trial Updated:
05/29/2024
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Melanoma (Skin), Skin Cancer
Register for Updates
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
NCT06299748
Recruiting
This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod any time within 25 days prior to conception or any time during pregnancy. Women exposed to efgartigimod only during breastfeeding will also be eligible to enroll. Background rates of major congenital malformations (MCMs) will be obtained from populations within the same countries/regions as the countries/regions in which the VYVGART IV or SC-exposed pregnancies were reported.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: United BioSource LLC, Morgantown, West Virginia
Conditions: Myasthenia Gravis
Register for Updates
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
NCT04763200
Recruiting
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/29/2024
Locations: West Virginia University Hospital, Morgantown, West Virginia
Conditions: Left Ventricular Dysfunction, Coronary Artery Disease
Register for Updates
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
05/29/2024
Locations: West Virginia University Healthcare, Morgantown, West Virginia
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
All
Ages:
30 years and above
Trial Updated:
05/28/2024
Locations: WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates